secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001104659-22-127798
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics appoints Gianluca Fuggetta as Principal Accounting Officer
----------------------------------------------------------------------------

- Gianluca Fuggetta, Finance Director Corporate Reporting since July 2022, appointed Principal Accounting Officer effective Dec 12, 2022.
- Prior to Gain Therapeutics, Fuggetta spent nearly 9 years at PricewaterhouseCoopers, most recently as Assurance Manager.
- CFO Salvatore Calabrese, who previously served as both Principal Financial and Accounting Officer, will continue as Principal Financial Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465922127798/0001104659-22-127798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465922127798/tm2232896d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-127798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer